These FAQs outline key recommendations and practical takeaways from the AUA/SUFU/AUGS Genitourinary Syndrome of Menopause guideline.
|Articles|December 1, 2010
Submit your coding questions to Ray Painter, MD, and Mark Painter
Send your question to our coding/reimbursement experts Ray Painter, MD, and Mark Painter.
Advertisement
Have a question about coding or reimbursement? Send your question to our coding/reimbursement experts Ray Painter, MD, and Mark Painter c/o Urology Times. To submit your question, use the "Post a Comment" form below.
Advertisement
Related to this article
Sandip M. Prasad, MD, MPhil, discusses 3-year ENVISION trial data showing durable responses with mitomycin intravesical solution for recurrent LG-IR-NMIBC.
Armine K. Smith, MD, discusses sexual health counseling, sex-specific considerations, and organ-preserving approaches for patients undergoing radical cystectomy.
This approval expands the label for nogapendekin alfa inbakicept to include patients with high-grade papillary-only tumors.
Melissa Hadley Barrett discusses real-world outcomes and tolerability of intranasal vardenafil for men with persistent erectile dysfunction despite prior standard therapy.
The completion of the first procedure marks the beginning of a controlled US commercial release.
Delayed diagnosis and skipped nodal staging worsen penile cancer outcomes, according to Luis G. Medina, MD.
Butterfly Medical has also submitted a premarket approval application to the FDA.
Advertisement
Advertisement
Trending on Urology Times
1
Urocross Expander System enters US commercial use for symptomatic BPH
2
Study assesses real-world outcomes with intranasal vardenafil for ED
3
FDA approves nogapendekin alfa inbakicept plus BCG for papillary-only BCG-unresponsive NMIBC
4
Matching mCSPC treatment to the patient, not just the trial data
5